|1.||Januzzi, James L: 69 articles (12/2015 - 12/2004)|
|2.||Cleland, John G F: 24 articles (06/2015 - 02/2006)|
|3.||Bayes-Genis, Antoni: 23 articles (09/2015 - 01/2006)|
|4.||Richards, A Mark: 20 articles (12/2015 - 01/2005)|
|5.||Baggish, Aaron L: 20 articles (05/2013 - 12/2004)|
|6.||Hildebrandt, Per: 20 articles (05/2012 - 03/2004)|
|7.||Pinto, Yigal M: 18 articles (12/2015 - 02/2006)|
|8.||Pacher, Richard: 17 articles (12/2015 - 08/2006)|
|9.||Mueller, Christian: 17 articles (11/2015 - 11/2005)|
|10.||Clark, Andrew L: 17 articles (11/2015 - 02/2006)|
07/17/2007 - "By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. "
03/01/2007 - "While a strategy where initial NTproBNP estimation is cost effective in detecting any causes of heart failure, portable echocardiography remains the most costeffective strategy to assess patients from the community with suspected heart failure."
03/01/2011 - "ST2 is a potent marker of risk in chronic heart failure and when used in combination with NT-proBNP offers moderate improvement in assessing prognosis beyond clinical risk scores."
12/01/2013 - "Left ventricular ejection fraction improved from 27 ± 8 % to 35 ± 10 %, left ventricular end-diastolic diameters were reduced from 65 ± 10 mm to 59 ± 5 mm. Median NT-proBNP was reduced from 1,886 to 997 pg/ml, QRS duration diminished from 158 ± 34 to 147 ± 27 ms. In conclusion, the Austrian data from the CRT survey confirms the efficacy of CRT in heart failure patients, but outlines that these patients still suffer from a high mortality and cardiovascular (CV) hospitalisation rate."
10/01/2009 - "The emergence of BNP or NT-proBNP testing has improved the management of acutely decompensated heart failure patients significantly by aiding in early recognition, prognostication, and treatment. "
|2.||Dyspnea (Shortness of Breath)
12/01/2010 - "Dyspnea patients with elevated NT-proBNP concentrations and no improvement in either NT-proBNP or QOL at 30-days are at high risk of mortality and HF hospitalization. "
06/19/2007 - "In a universal health coverage system mandating judicious use of healthcare resources, inclusion of NT-proBNP testing improves the management of patients presenting to emergency departments with dyspnea through improved diagnosis, cost savings, and improvement in selected outcomes."
09/01/2014 - "The aim of this study was to evaluate the association between NT-proBNP and the stages of renal dysfunction in a typical population attended to emergency department with acute dyspnea. "
06/01/2013 - "A total of 1,445 patients attending the emergency department with acute dyspnea had measurements taken of MR-proANP, BNP, and NT-proBNP values on enrollment to the BACH trial and were grouped according to presence or absence of AF and HF. "
01/01/2012 - "The aim of the present study was to relate NT-proBNP plasma levels to different stages of renal function assessed with different methods in older adult subjects admitted because of dyspnea. "
12/01/2014 - "The addition of NT-proBNP to multivariate models improved the C-index by 0.019 for the 'hard' cardiac endpoint (fatal and non-fatal myocardial infarction). "
03/01/2008 - "The inclusion of NT-proBNP improved the accuracy of the model for death or myocardial infarction (C-statistic 0.84 versus 0.76, p = 0.01). "
08/01/2015 - "The authors conducted a systematic review of studies reporting the ability of preoperative NT-proBNP measurements to predict the composite outcome of all-cause mortality and nonfatal myocardial infarction at 30 days after noncardiac surgery. "
06/01/2015 - "NT-proBNP and hs-cTnT were measured at baseline and after 2 to 3 years in older adults without prior HF or myocardial infarction in the CHS (Cardiovascular Health Study). "
02/01/2011 - "The purpose of the study was to determine whether NT-proBNP levels measured upon hospital admission of ST-segment elevation myocardial infarction (STEMI) patients receiving primary PCI have predictive value for MVO. "
06/04/2013 - "NT-proBNP improves risk stratification beyond the CHA2DS2VASc score and might be a novel tool for improved stroke prediction in AF. "
08/01/2014 - "We selected original studies reporting the performance of BNP or N-terminal probrain natriuretic peptide (NT-proBNP) in diagnosing CE stroke and summarized test performance characteristics using forest plots, hierarchical summary receiver operating characteristic curves, and bivariate random-effect models. "
01/01/2014 - "Cox proportional-hazards regression was used to study the incidence of stroke in relationship to NT-proBNP and MR-proANP. "
12/03/2013 - "Literature-based meta-analysis included 3,498 stroke patients from 16 studies and revealed that BNP/NT-proBNP levels were 255.78 pg/mL (95% confidence interval [CI] 105.10-406.47, p = 0.001) higher in patients who died; publication bias entailed the loss of this association. "
11/01/2007 - "Two studies revealed that NT-proBNP is more significant than clinical stroke severity for stroke mortality. "
|5.||Cardiovascular Diseases (Cardiovascular Disease)
03/01/2014 - "If confirmed, these novel results suggest that NT-proBNP, as well as aiding cardiovascular disease risk assessment, may also help assess the efficacy of specific antihypertensive regimens. "
04/01/2008 - "5. Thus, monitoring of BNP and NT-proBNP levels offers the possibilities of improved targeting of individuals with increased cardiovascular risk and optimization of strategies for primary and secondary prevention of cardiovascular disease. "
07/01/2015 - "We examined plasma NT-proBNP levels according to race/ethnicity in 3,148 individuals (51% black, 31% white, 18% Hispanic) free of prevalent cardiovascular disease in the Dallas Heart Study. "
01/01/2015 - "The purpose of this study was to evaluate the diastolic function of LV and level of NT-proBNP in people of different ages free of cardiovascular diseases and to assess their relationship with LTL. "
08/01/2014 - "The aim of this study was to investigate the association of NT-proBNP with cognitive function and decline in older adults at high risk of cardiovascular disease. "
|1.||Brain Natriuretic Peptide (Natrecor)
|2.||Biological Markers (Surrogate Marker)
|5.||pro-brain natriuretic peptide (1-76)
|8.||Troponin T (T, Troponin)
|10.||Atrial Natriuretic Factor (ANF)
|1.||Drug Therapy (Chemotherapy)
|2.||Cardiac Resynchronization Therapy
|5.||Renal Dialysis (Hemodialysis)